Aethlon Medical, Inc. — Form 10-Q Summary
Reporting period: Quarter ended June 30, 2016 (first quarter of fiscal 2017). The company develops the Hemopurifier and related ADAPT platform for therapeutic filtration, and pursues exosome-based diagnostics through its 80%-owned subsidiary, Exosome Sciences (ESI).
Financial performance and liquidity
| Metric | Quarter ended June 30, 2016 | Prior-year quarter |
|---|---|---|
| Revenue | $4,635 | $192,508 |
| Operating expenses | $1,136,287 | $1,282,479 |
| Operating loss | $(1,131,652) | $(1,089,971) |
| Net loss before noncontrolling interests | $(2,136,549) | $(1,216,659) |
| Net loss attributable to common stockholders | $(2,128,817) | $(1,183,036) |
| Basic and diluted loss per share | $(0.28) | $(0.18) |
| Cash used in operating activities | $(827,933) | $(798,006) |
Revenue was government-contract revenue; no product revenue or gross-margin measure was reported. The revenue decline primarily reflects no DARPA milestone invoice in the 2016 quarter, versus $186,164 invoiced in the prior-year quarter. Lower payroll and general and administrative costs reduced operating expenses, partly offset by higher professional fees. Operating loss nevertheless increased.
Net loss worsened substantially, mainly due to reported charges of $616,889 for debt extinguishment and $345,841 for warrant repricing; interest and other debt expense was $42,167. The filing describes the $80,000 note-extension fee as added to principal, not paid in cash. Cash and cash equivalents were $1,294,259 at June 30, down from $2,123,737 at March 31. Working capital was $848,795, versus $1,849,891 at March 31. Total liabilities were $1,085,781, including $616,817 in net noncurrent convertible notes; the notes’ principal was $692,811 and bears 10% interest.
Material changes, financing, and outlook
- On June 27, the company extended its November 2014 convertible notes’ maturity from June 1, 2016 to July 1, 2017, reduced the conversion price from $5.60 to $5.00 per share, and increased principal to $692,811, including accrued interest and an $80,000 extension fee. It also reduced the exercise price of related warrants from $8.40 to $5.00 and issued 30,000 additional warrants.
- On June 28, the company established an at-the-market (ATM) program with H.C. Wainwright for up to $12.5 million of common stock sales, subject to company instructions and a 3% commission. In July, it began sales; by August 11, it had raised $39,655 net from 6,100 shares.
- Management said substantial additional financing is needed to fund operations and clinical development. The filing states that continuing losses, limited working capital, and an accumulated deficit of approximately $88.6 million raise substantial doubt about the company’s ability to continue as a going concern. Management expected cash on hand, additional debt or equity financing, and government-contract receipts to meet needs through June 30, 2017, but gave no assurance that financing would be available.
- After quarter-end, DARPA authorized a new MERS in-vitro extraction milestone with a fixed payment of $193,719. The filing does not report receipt of this payment.
- On August 9, the board granted restricted stock units to officers and directors, including 634,000 RSUs to the CEO and grants to other executives and directors. These post-quarter awards may be relevant to future dilution and compensation expense.
Development, risks, and other disclosures
The Hemopurifier remained investigational. The FDA had authorized a 10-patient feasibility study for dialysis patients with hepatitis C, but the filing said patient recruitment had only recently begun; successful human trials and further regulatory steps are required before U.S. commercialization. DARPA payments depend on milestone achievement and acceptance. The company also cited risks involving financing availability, regulatory approval, patent protection, product liability, market acceptance, and competition. Some patents may expire before product approval. The company reported no pending or threatened legal proceedings and no off-balance-sheet arrangements. Management assessed disclosure controls as effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Progress and enrollment in the Hemopurifier feasibility study, and the additional trial and regulatory requirements for commercialization.
- Actual ATM proceeds, share issuance, and remaining capacity under the $12.5 million program; the filing reports only $39,655 net proceeds through August 11.
- Availability and terms of additional financing, cash burn, and whether management’s stated funding expectation through June 30, 2017 is achievable.
- Terms and accounting for the amended convertible notes and repriced warrants, including potential conversion or exercise dilution.
- Achievement, acceptance, invoicing, and collection of the new $193,719 DARPA milestone and any other contract milestones.
- Potential dilution and expense from the August 9 RSU grants; verify vesting, final agreements, and share counts.